A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica by Gebregiworgis, Teklab et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Jay Reddy Publications Veterinary and Biomedical Sciences, Department of
1-2016
A Urinary Metabolic Signature for Multiple
Sclerosis and Neuromyelitis Optica
Teklab Gebregiworgis
University of Nebraska–Lincoln
Helle H. Nielsen
University of Southern Denmark
Chandirasegara Massilamany
University of Nebraska-Lincoln, cmassilamany@unl.edu
Arunakumar Gangaplara
University of Nebraska–Lincoln
Jay Reddy
University of Nebraska-Lincoln, jayreddy@unl.edu
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/vbsjayreddy
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons,
Biochemical Phenomena, Metabolism, and Nutrition Commons, Medical Biochemistry Commons,
Neurology Commons, Neurosciences Commons, and the Reproductive and Urinary Physiology
Commons
This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Jay Reddy Publications by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Gebregiworgis, Teklab; Nielsen, Helle H.; Massilamany, Chandirasegara; Gangaplara, Arunakumar; Reddy, Jay; Illes, Zsolt; and
Powers, Robert, "A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica" (2016). Jay Reddy Publications. 27.
http://digitalcommons.unl.edu/vbsjayreddy/27
Authors
Teklab Gebregiworgis, Helle H. Nielsen, Chandirasegara Massilamany, Arunakumar Gangaplara, Jay Reddy,
Zsolt Illes, and Robert Powers
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/vbsjayreddy/27
Introduction 
Multiple sclerosis (MS) is a chronic disease of the central 
nervous system (CNS) with both neurodegenerative and in-
flammatory demyelinating components.1 The disease has a het-
erogeneous clinical presentation and is characterized by clinical 
symptoms that involve different parts of the CNS. Especially in 
the early stages, MS shares features with other demyelinating 
diseases like neuromyelitis optica-spectrum disorders (NMO-
SD).2 Despite recently updated classification criteria,3,4 differ-
entiation between the two diseases can be difficult but never-
theless vital, because misclassification can lead to increased 
disease activity due to incorrect treatment.5 Thus, the identifi-
cation of metabolite biomarkers for MS may help improve MS 
diagnostic protocols and help better understand the pathogen-
esis of the disease. 
Metabolite biomarkers are small chemical entities (<1500 
Da) found in biofluids where their presence or concentra-
tion has a correlation with either the prognosis, existence, 
or progression of a disease or the therapeutic response to a 
medication or treatment.6 Metabolites are the end products of 
enzymatic reactions or protein activity that are readily mod-
ulated by genetic alterations, environmental stress, toxins, or 
drugs.7 Thus, all phenotypic alteration caused by a disease or 
a medical treatment is expected to exhibit a unique metabolic 
profile or fingerprint.8 The ability to accurately and efficiently 
detect these metabolic alterations presents a potential avenue 
for personalized medicine and disease diagnosis through the 
identification of metabolite biomarkers.9 Unlike a single gene 
or protein routinely used as a medical biomarker, a metabolo-
mics biomarker is commonly comprised of a dozen or more me-
tabolites and provides a highly unique signature that may in-
crease the likelihood of a correct diagnosis.10 
The analysis of urine to obtain a metabolic profile has a 
number of well-known advantages that includes ready avail-
ability; a rapid, easy, inexpensive, and noninvasive sample col-
lection procedure; the ability to collect multiple, large sam-
ples over a range of time-points; and well-established protocols 
for storing, handling, and examining urine samples.11 The 
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Abstract 
Urine is a metabolite-rich biofluid that reflects the body’s effort to 
maintain chemical and osmotic homeostasis. Clinical diagnosis routinely 
relies on urine samples because the collection process is easy and 
noninvasive. Despite these advantages, urine is an under-investigated 
source of biomarkers for multiple sclerosis (MS). Nuclear magnetic 
resonance spectroscopy (NMR) has become a common approach for 
analyzing urinary metabolites for disease diagnosis and biomarker 
discovery. For illustration of the potential of urinary metabolites for 
diagnosing and treating MS patients, and for differentiating between 
MS and other illnesses, 38 urine samples were collected from healthy 
controls, MS patients, and neuromyelitis optica-spectrum disorder (NMO-SD) patients and analyzed with NMR, multivariate 
statistics, one-way ANOVA, and univariate statistics. Urine from MS patients exhibited a statistically distinct metabolic signature 
from healthy and NMO-SD controls. A total of 27 metabolites were differentially altered in the urine from MS and NMO-SD patients 
and were associated with synthesis and degradation of ketone bodies, amino acids, propionate and pyruvate metabolism, tricarboxylic 
acid cycle, and glycolysis. Metabolites altered in urine from MS patients were shown to be related to known pathogenic processes 
relevant to MS, including alterations in energy and fatty acid metabolism, mitochondrial activity, and the gut microbiota. 
Keywords: urine biomarkers, multiple sclerosis, neuromyelitis optica-spectrum disorder, NMR, metabolomics, multivariate statistics 
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investigation of urine metabolites using nuclear magnetic res-
onance spectroscopy (NMR) is experiencing a rapid growth of 
interest, where NMR metabolomics is routinely being used for 
drug and biomarker discovery.12 NMR is an attractive tech-
nique because it requires minimal sample preparations and is 
able to simultaneously detect and quantify a variety of com-
pounds from a complex mixture without separation. NMR is 
commonly combined with multivariate statistics to efficiently 
identify and statistically validate the metabolomics profile.13 
To date, investigations into MS metabolite biomarkers has 
primarily focused on the analysis of cerebrospinal fluid (CSF) 
and serum samples from MS patients.14,15 Little attention has 
been given to the analysis of urine16 despite the fact that me-
tabolites excreted into urine are readily accessible and are eas-
ily detected compared to CSF or blood samples.16 We previously 
reported an NMR metabolomics analysis of urinary markers of 
MS using the animal model experimental autoimmune enceph-
alomyelitis (EAE).17 The results of our prior EAE animal study 
demonstrated the potential of using urine as a source of metab-
olite biomarkers for MS. Herein, we report an NMR metabolo-
mics analysis of human urine samples collected from healthy 
controls, MS patients, and NMO-SD patients. Our results dem-
onstrate a statistically significant difference in the urinary me-
tabolites observed between MS patients and healthy controls 
and between MS and NMO-SD patients. 
Methods and Materials 
Patient Information and Clinical Manifestation 
To ensure as much homogeneity as possible within the 
groups, we selected definite aquaporin-4 (AQP4)-seropositive 
NMO-SD patients with high antibody titers in the serum di-
rected against the water channel AQP4, and ensured that all 
were diagnosed according to the criteria proposed by Wing-
erchuk 2006.4 Seven of the patients had definite seropositive 
NMO, whereas 2 had seropositive NMO-SD in the form of optic 
neuritis (ON) and longitudinally extensive transverse myelitis 
(LETM) (Table 1 and Table S1). The mean age was 39.3 with a 
female predominance as expected,18 and all received immuno-
suppressive therapy in the form of azathioprine. 
Similarly, all MS patients were diagnosed with relapsing-
remitting MS (RR-MS) according to the McDonald’s 2010 cri-
teria19 and accordingly received immunomodulatory therapy. 
Among this group, 5 patients received first-line therapy (glat-
iramer acetate and interferon-β), 1 patient received second-line 
therapy (natalizumab), and 2 patients received no treatment 
(Table 1 and Table S1). The mean age was 44.6 years with a 
female predominance. On average, the age at disease onset 
is 34 years; however, none of these patients were newly diag-
nosed. All healthy subjects were healthy volunteers with no 
known neurological or autoimmune diseases. Neither MS nor 
NMO/NMO-SD patients had experienced a relapse within 30 
days of the sample collection. The study was conducted in ac-
cordance with both the Hungarian and Danish National Eth-
ics Committee (38.93.316-12464/KK4/2010, 42341-2/2013/EKU, 
S-20120066). 
Urine Collection 
Using the NMO-SD and MS database of the University of 
Pecs in Hungary, we collected urine samples from 9 patients 
with NMOSD seropositive for antibodies against AQP4, 8 pa-
tients with RRMS, and 7 healthy subjects. Treatment, age, and 
gender of the study populations are shown in Table 1 and Table 
S1. Urine samples were collected as spot urine in the morning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
before breakfast and administration of drug treatment and pro-
cessed within 2 h of collection. The time intervals between rep-
licate urine sample collections were variable. All patients were 
on chronic treatment as indicated in Table 1 and Table S1. Aza-
thioprine and glatiramer acetate were administered daily, in-
terferon β-1b every other day, and natalizumab was adminis-
tered once a month. In cases of interferon β-1b treatment, urine 
was collected the day after administration. Urine was collected 
the day before the monthly natalizumab infusion in the single 
patient treated with natalizumab. Samples were centrifuged 
at 20,000g for 20 min at room temperature (RT) to pellet cell 
debris, and the supernatants were stored at −80 °C until use. 
Except for one MS patient, two analytical replicate urine sam-
ples were obtained from each MS patient and each healthy 
subject. Conversely, only one urine sample was collected from 
each NMO-SD patient. 
NMR Sample Preparation 
The urine samples were thawed and then centrifuged at 
13000 rpm for 5 min at RT to remove any precipitate. Then, 
100 μL of each urine sample was transferred into a new Eppen-
dorf tube and mixed with 500 μL of 50 mM phosphate buffer 
in 99.8% D2O (Isotec, St. Louis, MO) at pH 7.2 (uncorrected); 
50 μM of 3- (trimethylsilyl) propionic acid-2,2,3,3-d4 (TMSP-d4) 
was added to each sample as a chemical shift reference. The 
urine samples were then transferred to a 5 mm NMR tube for 
NMR data acquisition. 
NMR Data, Collection, and Processing and Multivariate Sta-
tistical Analysis 
The one-dimensional (1D) 1H NMR experiments were col-
lected and processed as described previously.17 The NMR data 
processing and multivariate statistical analysis were accom-
plished using our MVAPACK software suite (http://bionmr.
unl. edu/mvapack.php).20 The 1D 1H NMR spectra were aligned 
with the icoshift algorithm when the full-resolution spectra 
were modeled using orthogonal projections to latent struc-
turediscriminant analysis (OPLS-DA). Alternatively, the 1D 
1H NMR spectra were binned using an intelligent adaptive bin-
ning algorithm when S-plots and a shared and unique structure 
Table 1. Demographic Data of Hungarian Cohort*
 HS  AQP4-NMO/NMO-SD MS  
 n = 7 n = 9 n = 8
Disease Subtype
NMO-SD 0  7 0
ON  0 1 0
LETM 0  1 0
RR-MS 0 0  8
Sex
   female 4  6  6
    male  3 3  2
mean age (range)  26.7 (25−30)  39.3 (22−55)  44.6 (31−70)
Treatment
   azathioprine 0 9  0
   natalizumab  0 0  1
  interferon β-1b 0 0 3
   glatiramer acetate  0 0  2
   none of the above  7 0 2
* HS, healthy subjects; AQP4, aquaporin 4; NMO, neuromyelitis optica; 
NMO-SD, neuromyelitis optica-spectrum disorder; MS, multiple sclero-
sis; ON, optic neuritis; LETM, longitudinally extensive transverse my-
elitis; RR-MS, relapsing-remitting multiple sclerosis
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(SUSplot) plot were generated from the OPLS-DA model. The 
data were normalized with a probabilistic quotient normaliza-
tion function and Pareto scaled prior to multivariate statistical 
analysis. Fractions of explained variation (R2 X and R2 Y) were 
computed during OPLS-DA model training. OPLS-DA models 
were internally cross-validated using 7-fold Monte Carlo cross-
validation to compute Q2 values, which were compared to a dis-
tribution of null model Q2 values in 1000 rounds of response 
permutation testing. Model results were further validated us-
ing CV-ANOVA significance testing. 
Metabolite Identification 
An SUS plot was generated from the OPLS-DA models us-
ing MVAPACK to compare the MS and NMO-SD group against 
healthy controls. The plot visualizes the correlation between 
predictive components of each model and was used to identify 
metabolite changes unique to either the MS or the NMO-SD 
group. The chemical shift information from the loadings and 
SUS plots were assigned to metabolites using Chenomx NMR 
suite 7.0 (Chenomx Inc., Edmonton, Alberta, Canada) and the 
Human Urine Metabolome database (http://www. urinemetab-
olome.ca/). A 1H chemical shift error of 0.08 ppm was used 
to match the experimental chemical shifts with database val-
ues. Metabolite pathway analysis was accomplished using the 
Metabolomics Pathway Analysis (MetPA) Web server (http:// 
metpa.metabolomics.ca/MetPA). 
One-Way ANOVA and Univariate Statistical Analysis 
One-way ANOVA and univariate calculations were con-
ducted using the R statistical package version 3.2.0.21 One-
way ANOVA was used to determine the statistical significance 
of individual metabolite differences between healthy, MS, and 
NMO-SD patients. Metabolites with a p-value ≤ 0.05 were then 
subjected to Tukey’s multiple comparison of means test to iden-
tify the set of metabolites that are statistically different be-
tween the paired groups.22 A Student’s t test was also applied to 
determine the statistical significance of metabolite differences 
between the two groups. The p-values from the Student’s t test 
were further adjusted using the Benjamini−Hochberg multiple 
hypothesis method.23  
Figure 2. (a) Back-scaled OPLS-DA loadings plot resulting from modeling of the 1D 1H NMR data matrix from human urine samples col-
lected from MS patients and healthy controls. (b) S-plot from the OPLS-DA model generated from binned 1D 1H NMR spectra from the MS 
and healthy controls data sets (Figure S1). The x- and y-axis of the S-plot measures the covariance and correlation, respectively. The green 
and red triangles identify metabolites with a relative increase or decrease in concentration in urine samples from MS patients compared 
to healthy controls, respectively. The blue triangles correspond to unknown metabolites. The black triangles correspond to all other bins or 
metabolites. The metabolites are labeled as follows: 1, 2-hydroxyisovalerate; 2, isovalerate; 3, 3-hydroxyisobutyrate; 4, propylene glycol; 5, 
3-hydroxybutyrate; 6, methylmalonate; 7, 3-hydroxyisovalerate; 8, lactate; 9, alanine; 10, acetate; 11, N-acetylglutamine; 12, acetone; 13, 
acetoacetate; 14, oxaloacetate; 15, succinate; 16, citrate; 17, creatine; 18, creatinine; 19, malonate; 20, choline-containing compounds; 21, tri-
methylamine N-oxide; 22, glycine; 23, phenylalanine; 24, phenylacetylglycine; 25, hippurate; and 26, xanthine.  
Figure 1. (a) OPLS-DA scores resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected from MS patients 
(cyan) and healthy controls (red). A statistically significant degree of separation is observed between the two experimental classes. The leave-
n-out cross-validation metrics are R2Y = 0.77 and Q2 = 0.39, and the CV-ANOVA and a response permutation test p-values are 7.8 × 10−4 and 
8.0 × 10−3, respectively. Ellipses enclose the 95% confidence intervals estimated by the sample means and covariances of each class. (b) Re-
sponse permutation testing results for OPLS-DA scores after 1000 random permutations of the group membership information (Y). The model 
significance is inferred from the degree of vertical separation between the null distribution (leftmost) and the true R2Y and Q2 values (right-
most). The apparent discretization along the correlation axis is a result of using binary class labels in Y.   
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Results 
Urine Metabolomics Signature for MS Patients 
A 1D 1H NMR spectrum was acquired for each of the 29 
urine samples collected from seven healthy individuals and 
eight patients previously diagnosed with MS. The 1D 1HNMR 
spectra capture a “snapshot” of the state of the urinary me-
tabolome and provides a direct means of determining if the 
metabolic profiles differ between healthy and MS patients. 
The NMR data set was modeled by OPLS-DA, and the result-
ing scores plot (Figure 1a) shows a clear separation between 
the healthy controls and MS patients. Importantly, all of the 
biological replicates were assigned to the correct class in the 
OPLS-DA scores plot. The leave-n-out cross-validation metrics 
of R2Y = 0.77 and Q2 = 0.39 indicates an acceptable level of fit 
and predictive ability. A reliable model is also indicated by a 
p-value of 7.8 × 10−4 from the CV-ANOVA test and a p-value 
of 8.0 × 10−3 from the response permutation test (Figure 1b). 
A back-scaled loadings plot was generated from the OPLS-
DA model to identify the spectral regions (metabolites) that pri-
marily contribute to the observed class separation in the scores 
plot (Figure 2a). Twenty-six metabolites are differentially 
altered in the urine samples collected from healthy individu-
als and MS patients. The identified metabolites are from met-
abolic pathways associated with energy metabolism, fatty acid 
synthesis, and gut microflora, which include amino acid deriv-
atives and amino acid degradation products (Table S2). An S-
plot was then used to identify the major contributors to these 
observed class differences in the OPLS-DA scores plot (Figures 
S1 and 2b). The S-plot identified creatinine, hippurate, 3-hy-
droxybutyrate, malonate, oxaloacetate, and trimethylamine N-
oxide as having the highest covariance and correlation (from 
the 26 metabolites) with the OPLS-DA model from the healthy 
and MS data sets. A one-way ANOVA analysis was performed 
for each metabolite identified from the multivariate statistical 
analysis to determine if a statistically significant difference ex-
ists between the healthy and MS groups. Metabolites with a 
p-value ≤ 0.05 were selected (Table S3) and further subjected 
to Tukey’s multiple comparisons of means test.22 This analysis 
indicated that the set of metabolites, including creatinine (p-
value = 4.2 × 10−4), 3- hydroxyisovalerae (p-value = 3.2 × 10−02), 
and oxaloacetate (p-value = 5.0 × 10−02) discriminate between 
healthy controls and MS patients (Figure S2). A Student’s t test 
followed by the Benjamini−Hochberg multiple hypothesis test 
Figure 4. (a) Back-scaled OPLS-DA loadings plot resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected 
from NMO-SD patients and healthy controls. (b) S-plot from the OPLS-DA model generated from binned 1D 1H NMR spectra from NMO-SD 
and healthy controls data sets (Figure S2). The x- and y-axis of the S-plot measures the covariance and correlation, respectively. The green 
and red triangles identify metabolites with a relative increase or decrease in concentration in urine samples from NMO-SD patients com-
pared to healthy controls. The blue triangles correspond to unknown metabolites. The black triangles correspond to all other bins or metab-
olites. The metabolites are labeled as follows: 6, methylmalonate; 8, lactate; 9, alanine; 10, acetate; 11, N-acetylglutamine; 12, acetone; 13, 
acetoacetate; 14, oxaloacetate; 15, succinate; 16, citrate; 17, creatine; 18, creatinine; 19, malonate; 20, choline-containing compounds; 21, tri-
methylamine N-oxide; 22, glycine; 23, phenylalanine; 24, phenylacetylglycine; 25, hippurate; and 27, timethylamine.   
Figure 3. (a) OPLS-DA scores resulting from modeling of the 1D 1H NMR data matrix from human urine samples collected from NMO-SD 
patients (cyan) and healthy controls (red). A statistically significant degree of separation is observed between the two experimental classes. 
The leave-n-out cross-validation metrics are R2Y = 0.93 and Q2 = 0.68, and the CV-ANOVA and a response permutation test p-values are 7.3 
× 10−3 and 0, respectively. Ellipses enclose the 95% confidence intervals estimated by the sample means and covariances of each class. (b) Re-
sponse permutation testing results for OPLSDA scores after 1000 random permutations of the group membership information (Y). The model 
significance is inferred from the degree of vertical separation between the null distribution (leftmost) and the true R2Y and Q2 values (right-
most). The apparent discretization along the correlation axis is a result of using binary class labels in Y.  
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(Figure S3) identified acetate and creatinine as statistically dif-
ferent between healthy controls and MS patients.23 The Ben-
jamini−Hochberg adjusted p-value, one-way ANOVA, and mul-
tivariate analyses are fundamentally distinct techniques that 
emphasize different aspects of the data and have no expecta-
tions of producing identical results. Thus, a subset of the eight 
metabolites corresponding to acetate, creatinine, hippurate, 
3-hydroxybutyrate, 3-hydroxyisovalerae, malonate, oxaloace-
tate, and trimethylamine N-oxide have the potential of differ-
entiating between healthy controls and MS patients. 
Urine Metabolomics Signature for NMO-SD Patients 
Because NMO-SD is an inflammatory demyelinating dis-
ease of the CNS similar to MS, but antibodies play a major role 
in the pathogenesis in contrast to the supposedly heteroge-
neous pathogenesis in MS, we considered NMO-SD as a valu-
able negative control for identifying biomarkers specific to MS.2 
A 1D 1H NMR spectrum was acquired for each of the 23 urine 
samples collected from seven healthy individuals and nine pa-
tients previously diagnosed with NMO-SD. The NMR data set 
was modeled by OPLS-DA, and the resulting scores plot (Fig-
ure 3a) shows a clear separation between the healthy controls 
and NMOSD patients. All of the biological replicates were as-
signed to the correct class in the OPLS-DA scores plot. The 
leave-n-out cross-validation metrics of R2Y = 0.93 and Q2 = 0.68 
indicates a reasonable level of fit and predictive ability. A re-
liable model is also indicated by a p-value of 7.3 × 10−3 from 
the CV-ANOVA test and a p-value of zero from the response 
permutation test (Figure 3b). A back-scaled loadings plot (Fig-
ure 4a) identified 20 metabolites differentially altered in the 
urine samples collected from healthy individuals and NMO-
SD patients. The identified metabolites are amino acids and 
amino acid derivatives, tricarboxylic acid (TCA) cycle interme-
diates, choline-containing compounds, and metabolites from 
the gut microflora (Table S2). An S-plot was then used to iden-
tify the major contributors to this observed class differences 
in the OPLS-DA scores plot (Figures S4 and 4b). The S-plot 
identified acetate, creatinine, 3- hydroxybutyrate, methylmalo-
nate, oxaloacetate, and succinate as having the highest covari-
ance and correlation (from the 20 metabolites) with the OPLS-
DA model from the healthy and NMO-SD data sets. A one-way 
ANOVA analysis was performed for each metabolite identi-
fied from the multivariate statistical analysis to determine if 
a statistically significant difference exists between the healthy 
and NMO-SD groups. Metabolites with a pvalue ≤ 0.05 were 
selected (Table S3) and further subjected to Tukey’s multiple 
comparisons of means test.22 This analysis indicated that the 
set of metabolites, including creatinine (pvalue 4.0 × 10−07), 
3-hydroxybutyrate (p-value 2.9 × 10−02), oxaloacetate (p-value 
2.7 × 10−02), and methylmalonate (p-value 2.6 × 10−06) discrim-
inates between healthy controls and NMOSD patients (Figure 
S2). A Student’s t test followed by the Benjamini−Hochberg 
multiple hypothesis test (Figure S3) also identified the same 
set of metabolites as statistically different between healthy 
controls and NMO-SD patients. Similar to our comparison be-
tween healthy controls and MS patients, we identified a sub-
set of the six metabolites corresponding to acetate, creatinine, 
3-hydroxybutyrate, methylmalonate, oxaloacetate, and succi-
nate that have the potential of differentiating between healthy 
controls and NMO-SD patients. 
Metabolite Pathway Analysis 
The complete list of 27 metabolites (Tables S2 and S4) 
differentially altered in urine samples collected from MS and 
NMO-SD patients relative to healthy controls were uploaded 
to the MetPA Web server. MetPA used the Homo sapiens path-
way library, the hypergeometric test for the over-representa-
tion analysis, and the out-degree centrality for the pathway 
topology analysis. MetPA estimates a metabolite’s relative im-
portance, provides a global overview of the metabolic changes, 
and assists in identifying important pathways associated with 
the disease phenotype. The synthesis and degradation of ke-
tone bodies, amino acid metabolism, propionate metabolism, 
pyruvate metabolism, the TCA cycle, and glycolysis were iden-
tified as high impact pathways in MS and NMO-SD patients 
(Figure 5 and Table S5). 
Urine NMR Metabolomics Signatures That Differentiate MS 
and NMO-SD Patients 
The two back-scaled loadings plots and the two S-plots 
were directly compared to identify metabolites that were dis-
tinctly altered in the urine samples from either MS or NMO-
SD patients relative to healthy controls (Figures 2 and 4 and 
Figure S5). Eight metabolites, alanine, hippurate, 2-hydroxy-
isovalerate, 3-hydroxybutyrate, isovalerate, malonate, oxalo-
acetate, and trimethylamine N-oxide were identified as being 
Figure 5. (a) SUS plot generated from the OPLS-DA models compare the MS and NMO-SD groups against healthy controls. NMR bins within 
the MS specific or NMO-SD specific regions of the SUS plot are labeled with red or blue triangles, respectively. The resulting chemical shift 
information from the SUS plot was assigned to metabolites using ChenomxNMRsuite 7.0. The metabolites are numbered accordingly: 1, 2-hy-
droxyisovalerate/isovalerate; 6, methylmalonate; 8, lactate; 9, alanine; 10, acetate; 16, citrate; 17, creatine; 21, trimethylamine N-oxide; and 
25, hippurate. (b) Overview of the pathway topology analysis produced by MetPa (http://metpa.metabolomics.ca/MetPA). The highest ranked 
pathways are numbered accordingly: 1, synthesis and degradation of ketone bodies; 2, propionate metabolism; 3, pyruvate metabolism; 4, 
TCA cycle; 5, alanine, aspartate, and glutamate metabolism; and 6, glycolysis or gluconeogenesis.    
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uniquely altered in urine samples from MS patients relative to 
NMO-SD patients. Eight other metabolites, acetate, acetone, 
citrate, creatine, creatinine, lactate, methylmalonate, and suc-
cinate were identified as being uniquely altered in urine sam-
ples from NMO-SD patients relative to MS patients. 
For further refinement of a metabolic signature unique to 
MS patients, an SUS plot (Figure 5a) was generated from the 
MS vs healthy and the NMO-SD vs healthy OPLS-DA models 
using binned NMR data (Figures S1 and S4). The two sets of 
metabolites identified from the overlaid back-scaled loading 
plots were then assigned to appropriate bins in the SUS plot. 
In this manner, only metabolites that clearly fell within the 
MS specific or NMO-SD specific regions of the SUS plot were 
identified as statistically significant and retained. This analysis 
reduced the number of urine metabolites specific to MS (2-hy-
droxyisovalerate, alanine, hippurate, isovalerate, trimethyl-
amine N-oxide) or to NMO-SD (acetate, creatine, lactate, meth-
ylmalonate, and citrate) to five each. 
The results of the multivariate statistical analysis was fur-
ther supported by a follow-up univariate analysis.24 A one-way 
ANOVA analysis was performed for each metabolite identified 
from the multivariate statistical analysis to determine if a sta-
tistically significance difference exists between the healthy, 
MS, and NMO-SD groups. Metabolites with a p-value ≤ 0.05 
were selected (Table S3) and further subjected to Tukey’s mul-
tiple comparisons of means test.22 This analysis indicated that 
the set of metabolites, including creatinine (p-value = 1.5 × 
10−02), 3-hydroxybutyrate (p-value = 8.0 × 10−3), 3-hydroxyiso-
valerate (p-value = 8.4 × 10−05), and methylmalonate (p-value 
= 1.1 × 10−4), discriminate between MS and NMO-SD patients 
(Figure S2). An identical set of metabolites was also obtained 
using the Student’s t test followed by the Benjamini−Hoch-
berg multiple hypothesis test (Figure S−3).23 It is important 
to note that, in addition to being identified by the univariate 
analysis, 3-hydroxybutyrate was also identified in both S-plots 
but was absent in the SUS plot. 3-Hydroxybutyrate was likely 
missing in the SUS plot due to a serendipitous cancellation be-
cause it was located in opposite regions in the two S-plots (Fig-
ures 2 and 4). 
Discussion 
A wide range of chemicals from food, medication, envi-
ronmental contaminants, normal biological processes, and dis-
ease conditions are routinely excreted into the urine to main-
tain chemical homeostasis. Consequently, urinalysis has been 
used to diagnose diseases and evaluate a patient’s well-being 
for years. More recently, there has been a growing interest in 
identifying urinary metabolite biomarkers to monitor the prog-
nosis, existence, or progression of various cancers, cardiovas-
cular diseases, and neurological diseases.25 Despite the high-
rate of misdiagnosis, little attention has been paid toward the 
analysis of urinary metabolites for diagnosing MS.26 To address 
this oversight, we previously demonstrated that urinary me-
tabolites can differentiate between EAE mice (prototypic dis-
ease model for MS) from healthy and fingolimod (MS drug)-
treated EAE mice.17 We extended this initial animal study by 
using NMR, multivariate statistics, one-way ANOVA, and uni-
variate statistics to analyze changes in urine samples collected 
from MS and NMO-SD patients. Although the sample size was 
limited, we were still able to observe a potentially unique met-
abolic signature in urine samples collected from MS patients. 
Importantly, the MS metabolic signature was likely to be dis-
tinct from the urinary metabolites identified for NMO-SD 
patients. Our results are also consistent with a recent study by 
Moussallieh et al.15 that showed an increase in serum acetate 
levels in NMO-SD patients relative to MS patients. However, 
the limited sample size requires us to describe our statistical 
model and the set of potential urinary metabolite biomarkers 
as only a working hypothesis. A major revision may occur as 
the number of patients per group increases significantly. Nev-
ertheless, we are encouraged by the fact that we were able to 
link all of the metabolites and metabolic pathways identified 
from the urine of MS patients to known pathologic processes 
associated with MS. 
Glycolysis and the synthesis and degradation of ketone 
bodies were identified as two potentially high-impact path-
ways from our NMR metabolomics analysis of urine samples 
from MS patients. Specifically, we observed significant con-
centration changes in the glycolysis intermediates lactate and 
acetate and the ketone bodies 3-hydroxybutyrate and aceto-
acetate. This observation is consistent with basic brain chem-
istry that is expected to be altered by MS. The brain has a 
high energy need and uses 25% of the total available glucose. 
Interestingly, the brain also uses ketone bodies as an alter-
native energy source.27 Thus, alteration in glycolysis and the 
synthesis and degradation of ketone bodies is consistent with 
an alteration in energy generation. Besides energy genera-
tion, ketone bodies are also associated with fatty acid metab-
olism. This is pertinent because prior analysis of CSF and se-
rum samples from MS patients indicated altered energy and 
fatty acid metabolism.28 
The observed alterations in energy generation have led to 
the speculation that MS might be associated with mitochon-
drial defects.29 In fact, Witte et al. demonstrated an occurrence 
of severe mitochondrial defects in MS lesions.30 Because the mi-
tochondria are the primary source of energy in axons, the ob-
served defects would be expected to alter energy generation. In 
the mitochondria, ATP is produced via the TCA cycle, the elec-
tron transport chain (respiratory chain), and oxidative phos-
phorylation. From our NMR metabolomics analysis, we iden-
tified the TCA cycle as another possible high-impact pathway 
that was altered in the urine samples from MS patients. Inter-
mediates of the TCA cycle, such as citrate, oxaloacetate, and 
succinate were altered in the urine from MS patients. Of par-
ticular note, pyruvate and amino acid metabolism (alanine, as-
partate, and glutamate) pathways, which are directly coupled 
to the TCA cycle, were also identified as potential high-impact 
pathways. Defects in the amino acid metabolism pathway are 
known to cause a range of neurological issues.31 
We also observed an increase in creatine and a decrease in 
creatinine in the urine from MS patients. The creatine/ phos-
phocreatine/creatine kinase system is critical for maintaining 
energy levels in the brain and as a high-energy phosphate shut-
tle from the mitochondria to the cytoplasm.32 
Our NMR metabolomics analysis also identified propionate 
metabolism as another likely high-impact pathway altered in 
the urine of MS patients. Propionate (short-chain fatty acid) is 
primarily derived from the catabolism of lipids (fatty acid me-
tabolism) or proteins, where its accumulation is toxic and in-
hibits TCA cycle enzymes and cell growth.33 Propionate and 
propionyl-CoA are detoxified by the mitochondria through the 
methyl-malonyl-CoA pathway.34 Genetic flaws in the propio-
nate metabolism pathway cause faulty amino acid and fatty 
acid metabolism that lead to various neurological problems.34 
Thus, the observed alteration in propionate metabolism ap-
pears to be consistent with a recent view that MS may also be 
associated with dysfunction in lipid metabolism.35  
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Gut microbiota are known to establish a symbiotic rela-
tionship that provides essential health benefits to the host.36 
A similar correlation between gut microbiota and MS has been 
previously observed.36 In fact, Cantarel et al. described a differ-
ence in specific operational taxonomic units of gut microbiota 
in MS patients. Their finding also indicated that immunomod-
ulatory medications cause alterations in the gut microbiota of 
MS patients.37 Herein, we observed hippurate, a mammalian 
microbial cometabolite that was altered in the urine of MS pa-
tients. Propionate (described above) is also a metabolite of the 
gut microbiota. Thus, differences in urinary hippurate and pro-
pionate levels may be a result of a change in the gut microbi-
ota or alterations in the relevant metabolic pathway.38 Taken 
together, these findings suggest a potential role of gut micro-
biota in the pathogenesis and treatment of MS. 
Conclusions 
Although CNS and serum metabolites have been previ-
ously considered as a source of MS and NMO-SD biomarkers, 
we have demonstrated that the urine metabolome shows signif-
icant promise for investigating and diagnosing MS and NMO-
SD. We observed a set of eight potential urinary metabolites 
(acetate, creatinine, hippurate, 3-hydroxybutyrate, 3-hydroxy-
isovalerae, malonate, oxaloacetate, and trimethylamine N-ox-
ide) associated with MS that may be prospective biomarkers. 
Similarly, we observed a set of eight potential urinary metab-
olites (acetate, creatinine, 3-hydroxybutyrate, 3-hydroxyiso-
valerae, methylmalonate, oxaloacetate, and succinate) asso-
ciated with NMO-SD. Critically, we observed a distinct set of 
urinary metabolites (creatinine, 3-hydroxybutyrate, 3-hydroxy-
isovalerate, methylmalonate) that possibly differentiates MS 
from NMO-SD patients. This is despite the fact that NMO-SD 
is also an inflammatory immune-mediated disease of the CNS 
that was once considered a variant of MS. The observation 
that all of the metabolites and metabolic pathways identified 
from the urine of MS patients are linked to known pathologic 
processes associated with MS supports the potential reliabil-
ity of our study, although the sample size was small. Specif-
ically, metabolite changes are associated with alterations in 
energy and fatty acid metabolism, mitochondrial activity, and 
the gut microbiota. Although our results highlight the promise 
of urinary biomarkers as a tool to diagnose MS and NMO-SD, 
the limited sample size necessitates interpreting our results as 
only a proof-of-principle that requires further validation. It is 
possible that an increase in the number of patients per group 
may lead to a change in the observed set of urinary metabo-
lites that differentiates between MS patients, NMO-SD pa-
tients, and healthy controls. Nevertheless, as evident by a num-
ber of other recent MS and NMO-SD studies where practical 
considerations limit sample size,39−43 a conservative interpre-
tation does not negate the inherent scientific value of our ob-
servations. Instead, given the ease and ready access of urine 
samples from MS and NMO-SD patients, our results establish 
the urine metabolome as a potentially valuable resource for in-
vestigating the pathology of MS and NMO-SD for obtaining a 
rapid and reliable diagnosis and for monitoring a patient’s re-
sponse to treatment. 
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